- support
- info@evidentic.com
- +49 (0) 30 959 99 8831
Squamous Cell Carcinoma of the Head and Neck are cancers that are known collectively as head and neck cancers. Usually, they start in the squamous cells that line the mucosal surfaces of the head and neck (for example, those inside the mouth, throat, and voice box). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16.
Showing 1–12 of 20 results
ProductBatch | Antigen | Molecular Class | Drug Brand | Product Concentration | CoA | Quantity per vial | Storage Temperature | Expiry Date | Price from | |
---|---|---|---|---|---|---|---|---|---|---|
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
2019.11 |
197,00 € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
2020.01 |
197,00 € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
2021.05 |
197,00 € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
5 mg |
-80°C |
2021.09 |
329,00 € |
||
EGFR |
Monoclonal Antibody |
Erbitux® |
5 mg/mL |
– |
2 mg |
-80°C |
2021.11 |
197,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2025.05 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2025.03 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.08 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.10 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2018.02 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.05 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2019.01 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2020.09 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2020.11 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Opdivo® |
10 mg/mL |
– |
2 mg |
-80°C |
2021.02 |
316,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.07 |
528,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2018.12 |
528,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.03 |
528,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2019.07 |
528,00 € |
||
PD-1 |
Monoclonal Antibody |
Keytruda® |
25 mg/mL |
– |
2 mg |
-80°C |
2025.10 |
528,00 € |
Evidentic GmbH
Am Mühlenberg 10
14476 Potsdam | Germany